Pulmonary veno-occlusive disease in association with Hodgkin's disease

SJ CAPEWELL, AJ WRIGHT, DA ELLIS

From the Cardiothoracic Centre, Freeman Hospital, Newcastle upon Tyne

Pulmonary veno-occlusive disease is a rare cause of pulmonary hypertension of unknown aetiology. Pulmonary veno-occlusive disease is usually an isolated condition but has been reported in association with autoimmune vasculitis and may follow viral or toxoplasmal infection. We report a case of pulmonary veno-occlusive disease in association with Hodgkin's disease, a combination not previously described, and consider what treatment could be used to lower the pulmonary arterial pressure.

Case report

A 22 year old man, a gardener, who had previously been well, presented with a four month history of increasing dyspnoea, non-productive cough, retrosternal chest discomfort, and weight loss. On examination he had extensive acne vulgaris and bilateral axillary lymphadenopathy. The extremities were cool but no other abnormal physical signs were found. A biopsy specimen of a lymph node showed appearances of reactive hyperplasia. When reviewed four weeks later he was unable to walk more than about 45 metres on level ground because of breathlessness. He had sinus tachycardia, raised venous pressure, accentuation of the right ventricular impulse, a delayed and loud pulmonary second heart sound, and a third heart sound audible at the left sternal edge. No abnormal signs were found in the lungs.

The chest radiograph showed large proximal pulmonary arteries, widespread linear opacities and scattered micronodular opacities throughout the lung fields, and a small right pleural effusion. The electrocardiogram and the two dimensional echocardiogram showed right ventricular hypertrophy. The results of routine haematological, biochemical, and clotting studies and serum immunoglobulin and complement concentrations were normal. No evidence of recent viral or toxoplasmal infection was found. Tuberculin and Kveim test reactions were negative. Transbronchial lung biopsy specimens showed appearances of non-specific cellular infiltration of alveolar walls. An isotope lung scan showed normal ventilation but grossly disturbed perfusion suggestive of multiple pulmonary emboli. Right heart catheterisation confirmed the presence of severe pulmonary hypertension (86/29 mm Hg) and the mean pulmonary wedge pressure was recorded, with difficulty, as 31 mm Hg. Pulmonary angio-

Fig 1 Binucleated Sternberg Reed cell in a lymph node. (Haematoxylin and eosin, × 695.)

Address for correspondence (reprints will not be available): Dr DA Ellis, District General Hospital, Lowestoft Road, Gorleston, Great Yarmouth.

Accepted 1 February 1984
Pulmonary veno-occlusive disease in association with Hodgkin's disease

Fig 2. Pulmonary vein in an interlobular septum showing irregular fibroelastic intimal thickening. (Elastic van giesen, × 30.)

lesions or necrotising arteritis. There was no evidence of Hodgkin's disease in the lungs. Because of severe breathlessness empirical treatment was given with prednisolone 60 mg daily and azathioprine 150 mg daily pending the lung biopsy report. Anticoagulation with warfarin was started because of the risk of in situ thrombosis and the perfusion lung scan appearance. No improvement was seen after six weeks and the response to vasodilator agents and oxygen was studied. Pulmonary artery pressure with the patient breathing air was 91/41 (mean 65) mm Hg and while he was breathing 60% oxygen it fell to 66/31 (mean 43) mm Hg. After an isosorbide infusion (50 µg/min) it was 52/37 (mean 46) mm Hg and after oral hydralazine 150 mg per day for five days it was 47/22 (mean 31) mm Hg. Breathing 60% oxygen while he was receiving hydralazine lowered the pulmonary artery pressure to 33/17 (mean 23) mm Hg.

Fig 3. Haemosiderin laden macrophages within thick walled alveoli. (Perls' stain, × 78.)

Prednisolone was withdrawn and treatment with hydralazine, oxygen, azathioprine, and warfarin continued. Symptomatic improvement occurred over the next four weeks, with an increase in exercise tolerance to about 100 m on level ground. The patient was discharged from hospital and for four months there was no clinical deterioration, although symptoms were variable from day to day. He died suddenly while away from home on holiday five months after starting treatment with hydralazine and 12 months after the onset of symptoms. No necropsy was performed.

Discussion

Pulmonary veno-occlusive disease is a rare condition with a poor prognosis, most patients surviving less that two years from diagnosis. The diagnosis may be suspected when the clinical signs of pulmonary hypertension are accompanied by radiological signs of pulmonary oedema in the absence of structural heart disease but is usually made by histological examination of lung tissue obtained either at open lung biopsy or at necropsy. Treatment has been disappointing; corticosteroids have failed to produce improvement and vasodilators used briefly in one patient gave unconvincing results. The reported exception was a 46 year old woman with pulmonary veno-occlusive disease and autoimmune vasculitis who responded to azathioprine and was alive four years later. In our patient hydralazine produced a sustained fall in pulmonary arterial pressure that was enhanced by breathing 60% oxygen and we think that this was largely responsible for the observed clinical improvement, although prognosis was probably not affected. The association with Hodgkin's disease remains unexplained.

We are grateful to Professor D Heath for his report on the lung biopsy specimen, to Dr T Ashcroft for the photomicrographs, and to Dr S Nariman for permission to report the case.

References

S J Capewell, A J Wright and D A Ellis

*Thorax* 1984 39: 554-555
doi: 10.1136/thx.39.7.554

Updated information and services can be found at:
http://thorax.bmj.com/content/39/7/554.citation

**Email alerting service**

*These include:*
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/